Clinical Trials Directory

Trials / Completed

CompletedNCT07368855

GLP-1 Medicines and Mental Health Changes

Changes in Psychiatric Symptoms, Eating Disorder Behaviors, and Health Behaviors Following Six Months of GLP-1 Treatment for Obesity

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
90 (actual)
Sponsor
University of California, San Diego · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Key question: Is the use of GLP-1 weight loss medicines - semaglutide and tirzepatide - associated with improvements in mental health and health-related quality of life? Key finding: Across six- months of GLP-1 treatment, participants reported statistically significant improvements in mental health, eating disorder symptoms, and health-related quality of life domains such as pain interference and sleep quality. Message for readers: Although GLP-1 medicines are prescribed primarily for weight loss and metabolic health benefits, growing evidence suggests that these medicines may also facilitate meaningful improvements in mental health and quality of life.

Detailed description

In a sample of veterans with obesity and established metabolic disease receiving supervised GLP-1 treatment for weight loss, we observed a consistent pattern of improved psychiatric health, eating disorder behaviors, and health-related quality of life. In addition to observing statistically significant changes across all the latter dimensions using validated psychometric measures, effect size magnitudes were also large enough to suggest potentially clinically meaningful improvements. Importantly, we observed robust evidence of decreases in depressive symptoms - averaging 30% declines in symptom severity - with no signs of increased suicidal ideation symptoms in the sample. The smaller size of this sample necessarily warrants additional research to validate these findings across the broader veteran population and among non-veteran samples.

Conditions

Interventions

TypeNameDescription
DRUGGLP-1Wegovy or Zepbound

Timeline

Start date
2024-05-01
Primary completion
2025-07-01
Completion
2025-07-01
First posted
2026-01-27
Last updated
2026-01-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07368855. Inclusion in this directory is not an endorsement.

GLP-1 Medicines and Mental Health Changes (NCT07368855) · Clinical Trials Directory